United States-based Biohaven Pharmaceutical Holding Company Ltd (NYSE: BHVN) has named Robert J Hugin as its new director effective immediately, it was reported on Wednesday.
Hugin earlier served as the chairman and chief executive officer of Celgene Corporation. He joined Celgene as chief financial officer in 1999 and served in various positions including executive chairman, chief executive officer, president and chief operating officer. He also held the position of director of Chubb Limited, member of the Board of Trustees of Princeton University and chair of The Darden School Foundation, University of Virginia. Presently, he is the chair of the board of the Garden State Initiative and a longstanding member of the board of Trustees of Family Promise. He is past chairman of the boards of The Pharmaceutical Research and Manufacturers of America and the Healthcare Institute of NJ. He has also served as managing director with JP Morgan and Company Limited.
Declan Doogan, MD, chairman of Biohaven's board of irectors, said, 'We are excited to welcome Bob to Biohaven's board of directors as we have evolved to a commercial organization and look to the future. Having access to Bob's astute business and financial acumen will help Biohaven achieve our goal of becoming the leading pharmaceutical company focused on neuroscience indications.'
Futura Medical appoints Market Performance Group as new US distribution partner for Eroxon
MaaT Pharma to seek review after CHMP negative opinion on MaaT013 application
Sensei Biotherapeutics changes name to Faeth Therapeutics
Datavault AI and Wellgistics Health plan DelivMeds AI healthcare venture
Intensity Therapeutics receives Cancer Treatment Technology Innovator of the Year award
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits